Third-quarter earnings were ahead of Street expectations, driven mostly by robust growth in the drug division.
InflaRx Announces a $ 55M Series D Financing and Investment Round to Foster its Clinical Stage Complement Anti-C5a Development Programs
Kowa Pharmaceuticals America, Inc. Announces Court Decision to Uphold Patent Protection for Livalo® (pitavastatin calcium)
Rockwell Automation Demonstrates Commitment to Houston
Galen US Inc. Acquires First Inhaled Therapy Approved to Treat Agitation Associated with Schizophrenia and Bipolar I Disorder, Announces Revised Labeling